Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayur Narkhede

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2022
Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 RearrangementsSean Patrick Bliven, Lauren Shea, Susan Bal, et al.
JAMA Network Open|December 3, 2019
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic LeukemiaLindsey E Roeker, Maryam Sarraf Yazdy, Joanna Rhodes, et al.
Ejhaem|May 19, 2023
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)Mayur Narkhede, Nancy L Bartlett, Sami Ibrahimi, et al.
Plos One|March 10, 2017
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosisSurbhi Sidana, Mayur Narkhede, Paul Elson, et al.
Frontiers in Oncology|August 13, 2024
Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphomaMayur Narkhede, Sarah Tomassetti, Madiha Iqbal, et al.
Journal of Medical Economics|December 27, 2025
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGeorge Dranitsaris, Aaron Peevyhouse, Heather Neuhalfen, et al.
American Journal of Hematology|April 5, 2017
The association of histologic grade with acute graft-versus-host disease response and outcomesMayur Narkhede, Lisa Rybicki, Donna Abounader, et al.
American Journal of Hematology|December 1, 2023
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapseMatthew R Wilson, Amy A Kirkwood, Nicole Wong Doo, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2023
SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemiaKai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Plos Medicine|June 29, 2023
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort studyKai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2022
Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 RearrangementsSean Patrick Bliven, Lauren Shea, Susan Bal, et al.
JAMA Network Open|December 3, 2019
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic LeukemiaLindsey E Roeker, Maryam Sarraf Yazdy, Joanna Rhodes, et al.
Ejhaem|May 19, 2023
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)Mayur Narkhede, Nancy L Bartlett, Sami Ibrahimi, et al.
Plos One|March 10, 2017
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosisSurbhi Sidana, Mayur Narkhede, Paul Elson, et al.
Frontiers in Oncology|August 13, 2024
Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphomaMayur Narkhede, Sarah Tomassetti, Madiha Iqbal, et al.
Journal of Medical Economics|December 27, 2025
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGeorge Dranitsaris, Aaron Peevyhouse, Heather Neuhalfen, et al.
American Journal of Hematology|April 5, 2017
The association of histologic grade with acute graft-versus-host disease response and outcomesMayur Narkhede, Lisa Rybicki, Donna Abounader, et al.
American Journal of Hematology|December 1, 2023
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapseMatthew R Wilson, Amy A Kirkwood, Nicole Wong Doo, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2023
SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemiaKai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Plos Medicine|June 29, 2023
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort studyKai Qin, Kazuhito Honjo, Scott Sherrill-Mix, et al.
Pageof 3